Priothera is a clinical stage biotechnology company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Priothera is leading the way in developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Priothera was founded in 2020 by Drs. Florent Gros and Dhaval Patel. Joining the founding team are Dr. Christoph Bucher, Dr Simone Seiter, and Brice Suire. Priothera is headquartered in Dublin, Leinster, Ireland.
Priothera is dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in these patients.
Priothera has acquired Mocravimod, a modulator of sphingosine-1-phosphate (S1P) receptors. Mocravimod has already been extensively tested in multiple immunologic indications and has shown survival benefit in an early clinical study evaluating acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients undergoing hematopoietic stem cell transplantation (HSCT).
Priothera has closed a Series A financing round of €30M on Oct 12, 2020. The funding was led by Fountain Healthcare Partners with participation from co-lead investor HealthCap and funds managed by Tekla Capital Management, LLC as well as EarlyBird Venture Capital.